Does NIVOLUMAB Cause Hepatic cytolysis? 241 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 241 reports of Hepatic cytolysis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.3% of all adverse event reports for NIVOLUMAB.
241
Reports of Hepatic cytolysis with NIVOLUMAB
0.3%
of all NIVOLUMAB reports
11
Deaths
126
Hospitalizations
How Dangerous Is Hepatic cytolysis From NIVOLUMAB?
Of the 241 reports, 11 (4.6%) resulted in death, 126 (52.3%) required hospitalization, and 8 (3.3%) were considered life-threatening.
Is Hepatic cytolysis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 241 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Hepatic cytolysis?
ACETAMINOPHEN (1,469)
ATORVASTATIN (681)
PEMBROLIZUMAB (601)
CARBOPLATIN (577)
METHOTREXATE (468)
SULFAMETHOXAZOLE\TRIMETHOPRIM (356)
PACLITAXEL (324)
ENOXAPARIN (307)
AMOXICILLIN (273)
VALACYCLOVIR (261)
Which NIVOLUMAB Alternatives Have Lower Hepatic cytolysis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE